SEC Filings

Form 424B3
EXICURE, INC. filed this Form 424B3 on 11/06/2018
Document Outline
Entire Document (1305 KB)
Subdocument 1 - 424B3 - 424B3
Page 1 - Filed pursuant to Rule 424(b)(3)
Page 2 - UNITED STATES
Page 3 - N/A
Page 4 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 5 - N/A
Page 6 - PART I - FINANCIAL INFORMATION
Page 7 - EXICURE, INC.
Page 8 - EXICURE, INC.
Page 9 - EXICURE, INC.
Page 10 - EXICURE, INC.
Page 11 - EXICURE, INC.
Page 12 - EXICURE, INC.
Page 13 - EXICURE, INC.
Page 14 - EXICURE, INC.
Page 15 - EXICURE, INC.
Page 16 - EXICURE, INC.
Page 17 - EXICURE, INC.
Page 18 - EXICURE, INC.
Page 19 - EXICURE, INC.
Page 20 - EXICURE, INC.
Page 21 - EXICURE, INC.
Page 22 - EXICURE, INC.
Page 23 - EXICURE, INC.
Page 24 - EXICURE, INC.
Page 25 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 26 - XCUR17
Page 27 - microin vitroin vivo,
Page 28 - Recent Developments
Page 29 - Results of Operations
Page 30 - Research and development expense
Page 31 - Interest expense
Page 32 - Comparison of the Nine Months Ended September 30, 2018 and 2017
Page 33 - Research and development expense
Page 34 - Interest expense
Page 35 - Operating activities
Page 36 - Funding Requirements
Page 37 - Contractual Obligations and Commitments
Page 38 - Item 4. Controls and Procedures.
Page 39 - N/A
Page 40 - PART II OTHER INFORMATION
Page 41 - Our therapeutic candidates are in early stages of development and may fail in development or suffer
Page 42 - Product development involves a lengthy and expensive process with an uncertain outcome, and results
Page 43 - We will need substantial additional funds to advance the development of our therapeutic candidates,
Page 44 - Our quarterly operating results may fluctuate significantly or may fall below the expectations of in
Page 45 - If third parties on which we depend to conduct our preclinical studies and clinical trials do not pe
Page 46 - We may not successfully engage in strategic transactions, including any collaborations we seek, whic
Page 47 - We face competition from entities that have developed or may develop therapeutic candidates for our
Page 48 - Any inability to attract and retain qualified key management and technical personnel would impair ou
Page 49 - If our therapeutic candidates advance into clinical trials, we may experience difficulties in managi
Page 50 - Price controls imposed in foreign markets may adversely affect our future profitability.
Page 51 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 52 - We are subject to European data protection laws, including the new EU General Data Protection Regula
Page 53 - Our current operations are concentrated in one location and any events affecting this location may h
Page 54 - We have incurred significant losses since our inception and expect to incur continued losses in the
Page 55 - Association for Molecular Pathology v. Myriad Genetics, Inc.
Page 56 - We currently license patent rights from Northwestern University and may in the future license patent
Page 57 - inter alia
Page 58 - If we fail to comply with our obligations under any license, collaboration or other agreements, we m
Page 59 - We may be subject to claims that we or our employees or consultants have wrongfully used or disclose
Page 60 - Risks Related to Government Regulation
Page 61 - Certain of our therapeutic candidates may require companion diagnostics in certain indications. Fail
Page 62 - N/A
Page 63 - Any therapeutics we develop may become subject to unfavorable pricing regulations, third party cover
Page 64 - N/A
Page 65 - The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, an
Page 66 - Our ability to obtain services, reimbursement or funding from the federal government may be impacted
Page 67 - Significant developments stemming from the United Kingdom s recent referendum on membership in the E
Page 68 - Our stock price may be volatile and purchasers of our common stock could incur substantial losses.
Page 69 - The future issuance of equity or of debt securities that are convertible into equity may dilute your
Page 70 - The employment agreements with our executive officers may require us to pay severance benefits to of
Page 71 - The designation of our common stock as a penny stock would limit the liquidity of our common stock.
Page 72 - Anti-takeover provisions in our charter documents and under the General Corporation Law of the State
Page 73 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 74 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 75 - Item 6. Exhibits.
Page 76 - SIGNATURES
Page 77 - Exhibit 31.1
Page 78 - Exhibit 31.2
Page 79 - Exhibit 32.1

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet